Troxerutin

Summary

Troxerutin (CHEMBL3182320) is an approved small molecule (ATC C05CA04); indicated across 3 conditions including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C05CA04 (+1 more)
• Indications: 3 conditions
• Clinical trials: 2
• Chemistry: 742.7 Da · C33H42O19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3182320
Name	Troxerutin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5486699
ATC	C05CA04, C05CA54
Molecular formula	C33H42O19
Molecular weight	742.7
InChIKey	IYVFNTXFRYQLRP-VVSTWUKXSA-N

SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)OCCO)C5=CC(=C(C=C5)OCCO)OCCO)O)O)O)O)O)O

IUPAC name: 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one

Also known as: NSC-758937, Troxerutin, Troxerutina, Troxerutine, Z 6000, Z-6000, TROXERUTIN, SID144205003, troxerutin

Patent coverage: 1,742 distinct patent families (4,060 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 4,004 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADORA3	5.12	AC50	7523	nM	CHEMBL_ACT_25199160

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01848210	PHASE4	COMPLETED	Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
NCT06355258	PHASE1	RECRUITING	A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).